EGFR and non-small cell lung carcinoma: The proportion of tumors with NSCLC, clinical stage IV, excluding patients with EGFR/ALK mutation, where PD-L1 measurement was performed in the 2017 period (49%, N = 117), is considerably higher than the national average (32%, N = 1420).